Rick E. Winningham - 20 Feb 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
20 Feb 2025
Transactions value $
-$339,346
Form type
4
Filing time
24 Feb 2025, 19:32:45 UTC
Previous filing
22 Nov 2024
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Tax liability -$339K -35.1K -1.94% $9.66 1.78M 20 Feb 2025 Direct F1
holding TBPH Ordinary Shares 3.9K 20 Feb 2025 As Custodian
holding TBPH Ordinary Shares 92.6K 20 Feb 2025 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.